PackGene Wins Frost & Sullivan Gene Therapy Award
Analysis based on 6 articles · First reported Sep 11, 2026 · Last updated Sep 12, 2026
The award provides positive reputational recognition for PackGene Biotech Inc. within the gene therapy CRDMO sector, potentially enhancing its visibility among investors and partners. However, as a private company recognition event, the broader market impact is limited and unlikely to move public equity or credit markets materially.
On August 4, 2026, at the 20th Frost & Sullivan Global Growth, Innovation and Leadership Summit and the 5th New Investment Event held at Jing An Shangri-La in Shanghai, Frost & Sullivan awarded PackGene Biotech Inc. the Global Gene Therapy CRDMO Technology Innovation Leadership Award. The award recognizes PackGene's achievements in technological innovation, commercial success, and customer value in the gene therapy contract research, development, and manufacturing organization sector. The award was presented by Prof. Vinod K. Aggarwal, Global Chief Economist of Frost & Sullivan and Distinguished Professor at University of California, Berkeley, and Dr. Liu Jun, Chairman of the Frost & Sullivan Specialized & Sophisticated Enterprises Expert Committee and Chairman of Unicomp CJSC. PackGene, founded in 2014 and headquartered in Guangzhou, China, is a gene therapy CRDMO with operations in China, the United States, and Switzerland. The company has developed proprietary AAV manufacturing platforms, launched Asia's first cGMP AAV manufacturing facility in 2021, and opened a U.S. CDMO facility in December 2024. It has supported partners in securing more than ten FDA and NMPA IND approvals. The company is backed by investors including Sequoia Capital, SDIC Fund, and Cathay United Bank. The award highlights PackGene's role in advancing gene therapy manufacturing and its growing global footprint.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard